Fibrogenesis in Crohn's Disease

INTRODUCTION:Over one-third of patients with Crohn's disease (CD) will develop an intestinal stricture and the great majority of these will require at least one surgical procedure. While the pathogenesis of inflammation in CD has been extensively investigated, knowledge of stricture pathogenesis remains limited. The aim of this review is to discuss the current understanding of fibrogenesis in CD and to outline potential directions in research and therapeutics.METHODS:The electronic literature (January 1966 to May 2006) on CD-associated fibrosis was reviewed. Further references were obtained by cross-referencing from key articles.RESULTS:CD-associated fibrosis results from chronic transmural inflammation and a complex interplay among intestinal mesenchymal cells, cytokines, and local inflammatory cells. The fibroblast is the key cell type mediating stricture formation. The cytoarchitecure of the bowel wall is altered with disruption of the muscularis mucosa, thickening of the muscularis propria, and deposition of collagen throughout. The cytokine TGF-β appears critical in this process, acting to increase growth factor and extracellular matrix (ECM) production and dysregulate ECM turnover. Potential therapeutic interventions are likely to concentrate on modulating down-stream targets of TGF-β.CONCLUSIONS:Greater understanding of the biology of fibrostenosis is likely to yield significant advances in our ability to care for patients with stricturing CD. Potential dividends of this approach include identification of novel therapeutic targets and biomarkers useful for prognostication and therapeutic monitoring.

[1]  J. Fitzpatrick,et al.  Expression and regulation of connective tissue growth factor by transforming growth factor β and tumour necrosis factor α in fibroblasts isolated from strictures in patients with Crohn's disease , 2006 .

[2]  S. Hanauer,et al.  Factors Associated with the Development of Intestinal Strictures or Obstructions in Patients with Crohn's Disease , 2006, The American Journal of Gastroenterology.

[3]  L. Gesualdo,et al.  CD40L proinflammatory and profibrotic effects on proximal tubular epithelial cells: role of NF-kappaB and lyn. , 2006, Journal of the American Society of Nephrology : JASN.

[4]  P. Seksik,et al.  Prior appendectomy and the phenotype and course of Crohn's disease. , 2006, World journal of gastroenterology.

[5]  P. Rutgeerts,et al.  Review article: infliximab therapy for inflammatory bowel disease – seven years on , 2006, Alimentary pharmacology & therapeutics.

[6]  J. Mary,et al.  Ineffectiveness of Lactobacillus johnsonii LA1 for prophylaxis of postoperative recurrence in Crohn’s disease: a randomised, double blind, placebo controlled GETAID trial , 2005, Gut.

[7]  W. Hauswirth,et al.  IL-10 suppresses chemokines, inflammation, and fibrosis in a model of chronic renal disease. , 2005, Journal of the American Society of Nephrology : JASN.

[8]  J. Gauldie,et al.  Induction of a fibrogenic response in mouse colon by overexpression of monocyte chemoattractant protein 1 , 2005, Gut.

[9]  H. Verspaget,et al.  Expression of matrix metalloproteinases-2 and -9 in intestinal tissue of patients with inflammatory bowel diseases. , 2005, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

[10]  F. Galeazzi,et al.  TGF-β1 gene transfer to the mouse colon leads to intestinal fibrosis , 2005 .

[11]  P. Rutgeerts,et al.  Safety and tolerability of antagonist anti‐human CD40 Mab ch5D12 in patients with moderate to severe Crohn's disease , 2005, Alimentary pharmacology & therapeutics.

[12]  M. Yazdanbakhsh,et al.  Selective probiotic bacteria induce IL-10-producing regulatory T cells in vitro by modulating dendritic cell function through dendritic cell-specific intercellular adhesion molecule 3-grabbing nonintegrin. , 2005, The Journal of allergy and clinical immunology.

[13]  P. Rutgeerts,et al.  Ornidazole for prophylaxis of postoperative Crohn's disease recurrence: a randomized, double-blind, placebo-controlled trial. , 2005, Gastroenterology.

[14]  R. Kalluri,et al.  Bone Morphogenic Protein-7 Induces Mesenchymal to Epithelial Transition in Adult Renal Fibroblasts and Facilitates Regeneration of Injured Kidney* , 2005, Journal of Biological Chemistry.

[15]  Michael Karin,et al.  Nod2 Mutation in Crohn's Disease Potentiates NF-κB Activity and IL-1ß Processing , 2005, Science.

[16]  L. Beaugerie,et al.  Impact of the increasing use of immunosuppressants in Crohn’s disease on the need for intestinal surgery , 2005, Gut.

[17]  S. Gray,et al.  Time and Dose Effects of Mitomycin C on Extracellular Matrix Fibroblasts and Proteins , 2005, The Laryngoscope.

[18]  A. Senagore,et al.  Does Conversion of a Laparoscopic Colectomy Adversely Affect Patient Outcome? , 2004, Diseases of the colon and rectum.

[19]  M. Pines,et al.  Prevention of Fibrosis in Experimental Colitis by Captopril: the Role of tgf-β1 , 2004, Inflammatory bowel diseases.

[20]  R. Thisted,et al.  Postoperative maintenance of Crohn's disease remission with 6-mercaptopurine, mesalamine, or placebo: a 2-year trial. , 2004, Gastroenterology.

[21]  J. Fitzpatrick,et al.  Critical involvement of stress-activated mitogen-activated protein kinases in the regulation of intracellular adhesion molecule-1 in serosal fibroblasts isolated from patients with Crohn's disease. , 2004, Journal of the American College of Surgeons.

[22]  E. Fleck,et al.  Regulation of matrix metalloproteinase MT1-MMP/MMP-2 in cardiac fibroblasts by TGF-beta1 involves furin-convertase. , 2004, Cardiovascular research.

[23]  M. Goppelt‐Struebe,et al.  Differential effects of simvastatin on mesangial cells. , 2004, Kidney international.

[24]  P. Rutgeerts,et al.  A randomized, double-blind, placebo-controlled trial of the human anti-TNF-α monoclonal antibody adalimumab for the induction of remission in patients with moderate to severely active Crohn’s disease , 2004 .

[25]  E. Loftus.  Clinical epidemiology of inflammatory bowel disease: Incidence, prevalence, and environmental influences. , 2004, Gastroenterology.

[26]  Andrew Leask,et al.  TGF‐β signaling and the fibrotic response , 2004, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[27]  L. Eckmann.  Innate immunity and mucosal bacterial interactions in the intestine , 2004, Current opinion in gastroenterology.

[28]  J. Hugot.  Genetic Origin of IBD , 2004, Inflammatory bowel diseases.

[29]  P. Sime,et al.  Expression of CD154 (CD40 Ligand) by Human Lung Fibroblasts: Differential Regulation by IFN-γ and IL-13, and Implications for Fibrosis1 , 2004, The Journal of Immunology.

[30]  P. Rutgeerts,et al.  Medical Therapy for Crohn's Disease Strictures , 2004, Inflammatory bowel diseases.

[31]  J. Fitzpatrick,et al.  Increased vascular endothelial growth factor production in fibroblasts isolated from strictures in patients with Crohn's disease , 2004, The British journal of surgery.

[32]  J. Hugot,et al.  Lessons from Nod2 studies: towards a link between Crohn's disease and bacterial sensing. , 2003, Trends in immunology.

[33]  J. Willis,et al.  A murine model of chronic inflammation-induced intestinal fibrosis down-regulated by antisense NF-kappa B. , 2003, Gastroenterology.

[34]  Judy H. Cho,et al.  Defining Complex Contributions of NOD2/CARD15 Gene Mutations, Age at Onset, and Tobacco Use On Crohn's Disease Phenotypes , 2003, Inflammatory bowel diseases.

[35]  Shokei Kim,et al.  Regulation of IL-11 expression in intestinal myofibroblasts: role of c-Jun AP-1- and MAPK-dependent pathways. , 2003, American journal of physiology. Gastrointestinal and liver physiology.

[36]  S. Vukicevic,et al.  Bone morphogenetic protein‐7 reduces the severity of colon tissue damage and accelerates the healing of inflammatory bowel disease in rats , 2003, Journal of cellular physiology.

[37]  Gary R. Grotendorst,et al.  Connective tissue growth factor expression and action in human corneal fibroblast cultures and rat corneas after photorefractive keratectomy. , 2003, Investigative ophthalmology & visual science.

[38]  D. Abraham,et al.  Connective Tissue Growth Factor Gene Regulation , 2003, The Journal of Biological Chemistry.

[39]  B. Saunders,et al.  Long-Acting Steroid Injection after Endoscopic Dilation of Anastomotic Crohn’s Strictures May Improve the Outcome: A Retrospective Case Series , 2003, Endoscopy.

[40]  J. Belaiche,et al.  Early development of stricturing or penetrating pattern in Crohn’s disease is influenced by disease location, number of flares, and smoking but not by NOD2/CARD15 genotype , 2003, Gut.

[41]  M. Sans,et al.  The 4G/4G genotype of the 4G/5G polymorphism of the type‐1 plasminogen activator inhibitor (PAI‐1) gene is a determinant of penetrating behaviour in patients with Crohn's disease , 2003, Alimentary pharmacology & therapeutics.

[42]  S. Watson,et al.  Expression and regulation of tissue inhibitor of metalloproteinase-1 and matrix metalloproteinases by intestinal myofibroblasts in inflammatory bowel disease. , 2003, The American journal of pathology.

[43]  P. Knaus,et al.  Integration of the TGF-β pathway into the cellular signalling network , 2002 .

[44]  H. Ihn.  Pathogenesis of fibrosis: role of TGF-β and CTGF , 2002 .

[45]  D. Abraham,et al.  Prostacyclin derivatives prevent the fibrotic response to TGFβ2 by inhibiting the Ras/MEK/ERK pathway , 2002, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[46]  T. Keku,et al.  IGF-I and TGF-beta1 have distinct effects on phenotype and proliferation of intestinal fibroblasts. , 2002, American journal of physiology. Gastrointestinal and liver physiology.

[47]  R. Goldschmeding,et al.  Nitric oxide down-regulates connective tissue growth factor in rat mesangial cells. , 2002, Kidney international.

[48]  F. Carbonnel,et al.  Long-Term Evolution of Disease Behavior of Crohn's Disease , 2002, Inflammatory bowel diseases.

[49]  W. Rowe,et al.  Remicade® Does Not Abolish the Need for Surgery in Fistulizing Crohn’s Disease , 2002, Diseases of the colon and rectum.

[50]  M. Vatn,et al.  Association of NOD2 (CARD 15) genotype with clinical course of Crohn's disease: a cohort study , 2002, The Lancet.

[51]  M. Ferrini,et al.  Antifibrotic role of inducible nitric oxide synthase. , 2002, Nitric oxide : biology and chemistry.

[52]  T. Ahmad,et al.  The molecular classification of the clinical manifestations of Crohn's disease. , 2002, Gastroenterology.

[53]  C. O'Morain,et al.  CARD15/NOD2 mutational analysis and genotype-phenotype correlation in 612 patients with inflammatory bowel disease. , 2002, American journal of human genetics.

[54]  J. Fitzpatrick,et al.  Increased Adhesion Molecule Expression in Serosal Fibroblasts Isolated From Patients with Inflammatory Bowel Disease is Secondary to Inflammation , 2002, Annals of surgery.

[55]  B. Tran,et al.  Endothelin-1 stimulates human colonic myofibroblast contraction and migration , 2002, Gut.

[56]  J. Belaiche,et al.  Behaviour of Crohn's disease according to the Vienna classification: changing pattern over the course of the disease , 2001, Gut.

[57]  D. Abraham,et al.  Transforming growth factor-&bgr; and connective tissue growth factor: key cytokines in scleroderma pathogenesis , 2001, Current opinion in rheumatology.

[58]  T. Macdonald,et al.  Blocking Smad7 restores TGF-beta1 signaling in chronic inflammatory bowel disease. , 2001, The Journal of clinical investigation.

[59]  M. Goppelt‐Struebe,et al.  Rho‐dependent inhibition of the induction of connective tissue growth factor (CTGF) by HMG CoA reductase inhibitors (statins) , 2001, British journal of pharmacology.

[60]  C. Godson,et al.  Connective tissue growth factor: an attractive therapeutic target in fibrotic renal disease , 2001, Expert opinion on therapeutic targets.

[61]  D. Abraham,et al.  Iloprost suppresses connective tissue growth factor production in fibroblasts and in the skin of scleroderma patients. , 2001, The Journal of clinical investigation.

[62]  Mourad Sahbatou,et al.  Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn's disease , 2001, Nature.

[63]  D. Nicolae,et al.  A frameshift mutation in NOD2 associated with susceptibility to Crohn's disease , 2001, Nature.

[64]  E. Weiss,et al.  Laparoscopic surgery for inflammatory bowel disease , 2001, Surgical Endoscopy.

[65]  J. Church,et al.  Safety and longterm efficacy of strictureplasty in 314 patients with obstructing small bowel Crohn's disease. , 2001, Journal of the American College of Surgeons.

[66]  H. Freeman.  Application of the Montreal classification for Crohn's disease to a single clinician database of 1015 patients. , 2001, Canadian journal of gastroenterology = Journal canadien de gastroenterologie.

[67]  F. Farrokhyar,et al.  Low mortality in ulcerative colitis and Crohn's disease in three regional centers in England , 2001, American Journal of Gastroenterology.

[68]  M. Keighley,et al.  Wide-lumen stapled anastomosisvs. conventional end-to-end anastomosis in the treatment of Crohn's disease , 2001, Diseases of the colon and rectum.

[69]  R. Sartor,et al.  IGF-I and procollagen alpha1(I) are coexpressed in a subset of mesenchymal cells in active Crohn's disease. , 2000, American journal of physiology. Gastrointestinal and liver physiology.

[70]  P. Rutgeerts,et al.  Recombinant human interleukin 10 in the treatment of patients with mild to moderately active Crohn's disease , 2000 .

[71]  J. Abraham,et al.  CTGF expression is induced by TGF- beta in cardiac fibroblasts and cardiac myocytes: a potential role in heart fibrosis. , 2000, Journal of molecular and cellular cardiology.

[72]  J. Pucilowska,et al.  Fibrogenesis. IV. Fibrosis and inflammatory bowel disease: cellular mediators and animal models. , 2000, American journal of physiology. Gastrointestinal and liver physiology.

[73]  T. Macdonald,et al.  Imbalance of stromelysin-1 and TIMP-1 in the mucosal lesions of children with inflammatory bowel disease , 2000, Gut.

[74]  S. Rosewicz,et al.  Differential expression of matrix metalloproteinases and their tissue inhibitors in colon mucosa of patients with inflammatory bowel disease , 2000, Gut.

[75]  Toshiyuki Yamamoto,et al.  Monocyte Chemoattractant Protein-1 Enhances Gene Expression and Synthesis of Matrix Metalloproteinase-1 in Human Fibroblasts by an Autocrine IL-1α Loop1 , 2000, The Journal of Immunology.

[76]  J. Belaiche,et al.  Increased production of matrix metalloproteinase‐3 and tissue inhibitor of metalloproteinase‐1 by inflamed mucosa in inflammatory bowel disease , 2000, Clinical and experimental immunology.

[77]  Y. Yazaki,et al.  Long-term outcome of non-surgical strictureplasty using metallic stents for intestinal strictures in Crohn's disease. , 2000, Gastrointestinal endoscopy.

[78]  R. Cohen,et al.  The cost of hospitalization in Crohn's disease , 2000, American Journal of Gastroenterology.

[79]  D. Jewell,et al.  A Simple Classification of Crohn's Disease: Report of the Working Party for the World Congresses of Gastroenterology, Vienna 1998 , 2000, Inflammatory bowel diseases.

[80]  E. Bottinger,et al.  A mechanism of suppression of TGF–β/SMAD signaling by NF-κB/RelA , 2000, Genes & Development.

[81]  R. Tarnuzzer,et al.  Expression of matrix metalloproteinases and tissue inhibitor of matrix metalloproteinases in mesothelial cells and their regulation by transforming growth factor‐β1 , 1999, Wound repair and regeneration : official publication of the Wound Healing Society [and] the European Tissue Repair Society.

[82]  G. Camussi,et al.  Expression of CD40 and its ligand, CD40L, in intestinal lesions of Crohn's disease , 1999, American Journal of Gastroenterology.

[83]  Chun-xia Ma,et al.  Regulation of matrix metalloproteinases (MMPs) and their tissue inhibitors in human myometrial smooth muscle cells by TGF-beta1. , 1999, Molecular human reproduction.

[84]  P. Rutgeerts,et al.  Hyperexpression of CD40 ligand (CD154) in inflammatory bowel disease and its contribution to pathogenic cytokine production. , 1999, Journal of immunology.

[85]  A. Zinsmeister,et al.  Clinical course and costs of care for Crohn's disease: Markov model analysis of a population-based cohort. , 1999, Gastroenterology.

[86]  J. Murray,et al.  Laparoscopic colectomy: indications for conversion to laparotomy. , 1999, Archives of surgery.

[87]  D. Jewell,et al.  Oral budesonide for prevention of postsurgical recurrence in Crohn's disease. The IOIBD Budesonide Study Group. , 1999, Gastroenterology.

[88]  P. Rubin,et al.  Blockade of CD40-CD40 ligand interactions protects against radiation-induced pulmonary inflammation and fibrosis. , 1998, Clinical immunology and immunopathology.

[89]  Gary R. Grotendorst,et al.  Connective tissue growth factor: a novel regulator of mucosal repair and fibrosis in inflammatory bowel disease? , 1998, The international journal of biochemistry & cell biology.

[90]  C. Billington,et al.  Regulation of proliferation of human colonic subepithelial myofibroblasts by mediators important in intestinal inflammation. , 1998, The Journal of clinical investigation.

[91]  Jean Weissenbach,et al.  Mapping of a susceptibility locus for Crohn's disease on chromosome 16 , 1996, Nature.

[92]  P. Munkholm,et al.  Disease activity courses in a regional cohort of Crohn's disease patients. , 1995, Scandinavian journal of gastroenterology.

[93]  P. Rutgeerts,et al.  Controlled trial of metronidazole treatment for prevention of Crohn's recurrence after ileal resection. , 1995, Gastroenterology.

[94]  J. Tjandra,et al.  Long-term follow-up of strictureplasty in Crohn's disease , 1993, Diseases of the colon and rectum.

[95]  Richard O. Hynes,et al.  Integrins: Versatility, modulation, and signaling in cell adhesion , 1992, Cell.

[96]  H. Stein,et al.  Cellular localization of procollagen gene transcripts in inflammatory bowel diseases. , 1992, Gastroenterology.

[97]  M. Lark,et al.  Discoordinate expression of stromelysin, collagenase, and tissue inhibitor of metalloproteinases-1 in rheumatoid human synovial fibroblasts. Synergistic effects of interleukin-1 and tumor necrosis factor-alpha on stromelysin expression. , 1990, The Journal of biological chemistry.

[98]  P. Rutgeerts,et al.  Predictability of the postoperative course of Crohn's disease. , 1990, Gastroenterology.

[99]  W. Schürch,et al.  Differentiation repertoire of fibroblastic cells: expression of cytoskeletal proteins as marker of phenotypic modulations. , 1990, Laboratory investigation; a journal of technical methods and pathology.

[100]  E. O'Keefe.  Growth Factors and Other Aspects of Wound Healing: Biological and Clinical Implications , 1989 .

[101]  D. Sachar,et al.  Perforating and non-perforating indications for repeated operations in Crohn's disease: evidence for two clinical forms. , 1988, Gut.

[102]  R. Diegelmann,et al.  Collagen content and types in the intestinal strictures of Crohn's disease. , 1988, Gastroenterology.

[103]  R. Conigliaro,et al.  Endoscopic dilation of anastomotic colonic stenosis by different techniques: an alternative to surgery? , 1987, Gastrointestinal endoscopy.

[104]  S. Galandiuk,et al.  Strictureplasty in diffuse Crohn's jejunoileitis , 1985, Diseases of the colon and rectum.

[105]  R. Farmer,et al.  Recurrence after surgery in Crohn's disease. Relationship to location of disease (clinical pattern) and surgical indication. , 1985, Gastroenterology.

[106]  P. Rutgeerts,et al.  Natural history of recurrent Crohn's disease at the ileocolonic anastomosis after curative surgery. , 1984, Gut.

[107]  H. Ehrlich,et al.  The identification of αA and αB collagen chains in hypertrophic scar , 1981 .

[108]  R. Farmer,et al.  Indications for surgery in Crohn's disease: analysis of 500 cases. , 1976, Gastroenterology.

[109]  A. Bailey,et al.  Characterization of the collagen of human hypertrophic and normal scars. , 1975, Biochimica et biophysica acta.

[110]  J. Fitzpatrick,et al.  Expression and regulation of connective tissue growth factor by transforming growth factor beta and tumour necrosis factor alpha in fibroblasts isolated from strictures in patients with Crohn's disease. , 2006, The British journal of surgery.

[111]  J. Fitzpatrick,et al.  Transforming growth factor-beta promotes pro-fibrotic behavior by serosal fibroblasts via PKC and ERK1/2 mitogen activated protein kinase cell signaling. , 2005, Annals of surgery.

[112]  C. Jobin,et al.  Tumor Necrosis Factor (TNF) (cid:1) Increases Collagen Accumulation and Proliferation in Intestinal Myofibroblasts via TNF Receptor 2 * , 2005 .

[113]  P. Tighe,et al.  Differential expression of TGF-beta isoforms by normal and inflammatory bowel disease intestinal myofibroblasts. , 2002, American journal of physiology. Cell physiology.

[114]  Gary R. Grotendorst,et al.  Connective tissue growth factor is directly related to liver fibrosis. , 2002, Hepato-gastroenterology.

[115]  H. Ihn.  Pathogenesis of fibrosis: role of TGF-beta and CTGF. , 2002, Current opinion in rheumatology.

[116]  S. Targan,et al.  Mutations in NOD2 are associated with fibrostenosing disease in patients with Crohn's disease. , 2002, Gastroenterology.

[117]  C. Prantera,et al.  INFLAMMATION AND INFLAMMATORY BOWEL DISEASE Ineffectiveness of probiotics in preventing recurrence after curative resection for Crohn’s disease: a randomised controlled trial with Lactobacillus GG , 2002 .

[118]  P. Knaus,et al.  Integration of the TGF-beta pathway into the cellular signalling network. , 2002, Cellular signalling.

[119]  H. Freeman,et al.  Application of the Vienna Classification for Crohn's disease to a single clinician database of 877 patients. , 2001, Canadian journal of gastroenterology = Journal canadien de gastroenterologie.

[120]  P. Rutgeerts,et al.  Recombinant human interleukin 10 in the treatment of patients with mild to moderately active Crohn's disease. The Interleukin 10 Inflammatory Bowel Disease Cooperative Study Group. , 2000, Gastroenterology.

[121]  J. Fitzpatrick,et al.  Stricture formation in Crohn's disease: the role of intestinal fibroblasts. , 2000, Annals of surgery.

[122]  P. Majmudar,et al.  Topical mitomycin-C for subepithelial fibrosis after refractive corneal surgery. , 2000, Ophthalmology.

[123]  M. Bitzer,et al.  A mechanism of suppression of TGF-beta/SMAD signaling by NF-kappa B/RelA. , 2000, Genes & development.

[124]  H. Friess,et al.  Transforming growth factor-betas and their signaling receptors are coexpressed in Crohn's disease. , 1999, Annals of surgery.

[125]  H. Friess,et al.  Transforming Growth Factor-βs and Their Signaling Receptors Are Coexpressed in Crohn's Disease , 1999 .

[126]  D. Schuppan,et al.  Increased collagen type III synthesis by fibroblasts isolated from strictures of patients with Crohn's disease. , 1992, Gastroenterology.

[127]  C. Herfarth,et al.  Postoperative recurrence of Crohn's disease in relation to radicality of operation and sulfasalazine prophylaxis: a multicenter trial. , 1989, Digestion.

[128]  H. Ehrlich.  The role of connective tissue matrix in wound healing. , 1988, Progress in clinical and biological research.

[129]  Ehrlich Hp.  The role of connective tissue matrix in wound healing. , 1988 .

[130]  H. Ehrlich,et al.  The identification of alpha A and alpha B collagen chains in hypertrophic scar. , 1981, Experimental and molecular pathology.

[131]  O. Bonnevie,et al.  The Long-term Prophylactic Effect of Salazosulfapyridine (SalazopyrinR) in Primarily Resected Patients with Crohn's Disease , 1978 .

[132]  L. Bergman,et al.  Postoperative treatment with corticosteroids and salazosulphapyridine (Salazopyrin) after radical resection for Crohn's disease. , 1976, Scandinavian journal of gastroenterology.

[133]  I. Leodolter.  [Crohn's disease]. , 1967, Wiener Zeitschrift fur innere Medizin und ihre Grenzgebiete.